Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook {"summary":"","positive":[],"negative":[],"faq":[]}

#ENTA Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

www.stocktitan.net/news/ENTA/enanta-pharmac...

Feliz año nuevo gente les dejo este mini conjunto de la sra claus #enta #rule34 #happynewyear #merrychristmas #pack #digitalart

Enta Releases ‘Self Care EP’ on Neurofunk Label Eatbrain Enta's 'Self Care EP' features four technically complex neurofunk tracks shaped by heavy bass and detailed, rhythmic patterns. The post Enta Releases ‘Self Care EP’ on Neurofunk Label Eatbrain appeared first on EDM Identity.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 {"summary":"","positive":[],"negative":[],"faq":[]}

#ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

www.stocktitan.net/news/ENTA/enanta-pharmac...

Redraw of Fortuno by #beamattack64.bsky.social
#Fanart #Redraw #Fortuno #Sona #ArtRequest #Enta

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Avalo Therapeutics (NASDAQ:AVTX) Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS ) rose sharply in today's pre-market trading . Genmab announced plans to acquire...

#AVTX #BIAF #CGC #CLLS #CYCU #ENTA #ENTA #EPOW #JFB #LRMR #MLTX

Origin | Interest | Match

Leading Indicators, Tuesday September 23, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Tue Sept 23rd - #VERU #UPXI #TEAD #SATL #REAX #QURE #PRAA #OFS #MAXN #LIDR #GLTO #FIP #ENTA #DNUT #CLYM #WGO #TFIN #SKIL #NIC #LANV #EVH #CCS #BHE - More: crystalequityresearch.com/leading-indi... - #smallcap

Fanart of Fortuno by @beamattack64.bsky.social
#Fanart #Fortuno #Sona #ArtTrade #Enta

#ArabTrap4 #Enta #MoonKnight

www.youtube.com/watch?v=rh9E...

Trade Alerts, Wednesday September 10, 2025 – Crystal Equity Research

Small-cap stocks registering bearish MACD crossover signal, Wed Sept 10th - #ZEUS #STKL #RSVR #PHAT #OCFC #NATR #MIST #LKFN #IBEX #HCSG #FMBH #WASH #ENTA #DCOM #CBNK #BFC #ZEPP #UTZ #TRTX #SGU #RMAX #OLP #TASK #NIC #LXFR #IVR #HLF - More: crystalequityresearch.com/trade-alerts... - #smallcap

Major Patent Battle: Biotech Firm Enanta Challenges Pfizer's Paxlovid in Landmark EU Court Case Enanta Pharmaceuticals files patent infringement suit against Pfizer in EU's Unified Patent Court over COVID-19 drug Paxlovid. Decision expected within 12 months across 18 EU countries.

#ENTA Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

www.stocktitan.net/news/ENTA/enanta-pharmac...

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.

#ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

www.stocktitan.net/news/ENTA/enanta-pharmac...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.

#ENTA #RNTX #WVE XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

www.stocktitan.net/news/ENTA/xtal-pi-and-do...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Thu Jun 12th- #CTEV #KAR #LVWR #AUTL #CTRN #ENTA #IMRX #LOOP #TDUP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Jun 5th - #TBCH #SRDX #RIGL #OCUL #NATR #ENTA #DRIO #CRBP #BWMN #AEHL #WGO #SQNS #ORN #GHM #DBD #CPF #BV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

ENTA - Enanta Pharmaceuticals Inc Latest Stock News & Market Updates Stay updated with Enanta Pharmaceuticals (ENTA) news: Press releases, clinical trial updates, and partnership announcements in antiviral drug development.

#ENTA Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

www.stocktitan.net/news/ENTA/enanta-pharmac...

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2025 financial results with key developments in its virology and immunology pipeline. The company achieved target enrollment of 180 patients in RSVHR Phase 2 study of zelicapavir for RSV treatment, with topline data expected in late Q3 2025. Financial highlights include revenue of $14.9 million from MAVYRET royalties (down from $17.1M in Q2 2024), and a net loss of $22.6 million ($1.06 per share). Cash position stands at $193.4 million, further strengthened by a $33.8 million federal tax refund received in April 2025. The company's pipeline progress includes STAT6 program advancement with plans for development candidate selection in 2H 2025, and ongoing IND enabling studies for KIT inhibitor EPS-1421. Enanta expects current financial resources to fund operations into fiscal 2028.

#ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

www.stocktitan.net/news/ENTA/enanta-pharmac...

Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial First-in-class oral RSV drug demonstrates promising results in reducing disease severity and accelerating viral clearance. New data reveals respiratory benefits.

#ENTA Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

www.stocktitan.net/news/ENTA/enanta-pharmac...

all messages are opinion | Linktree do not assume accuracy no warranty is implied no liability of any kind exists

At Enanta Pharmaceuticals, Inc.'s #ENTA 2024 Annual Meeting of Stockholders on March 6, 2024, 20% of the votes were withheld.

#microcap #stockholderdemocracy #activistinvestor

Disclaimer

linktr.ee/disclaimer462

I paid
@lucdrawsthings.bsky.social for a commission of a male gender swap version of Enta. Thank you very much! #Enta #Disgaea #Genderswap #Genderbent

FINALLY HAVE A REF FOR HER (art by my friend)
#toytalerp #enta

Clearly cKIt (CD117) is not the right target to go after in CSU ! After Celldex #CLDX mAb in 09/24, Jasper #JSPR mAb in 01/25, today it's Third Harmonic #THRD small molecule to take the plunge. Enanta #ENTA SME is still preclinical. Inflarx #IFRX anti C5aR looks all the more promissing (Precli+ph1)

Enanta Pharma Slashes Losses 33% in Q1, Secures 4-Year Cash Runway | ENTA Earnings Enanta reports improved Q1 FY25 results with reduced losses, strong $216.7M cash position, and advancing clinical pipeline despite slight revenue decline to $17M.

#ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

www.stocktitan.net/news/ENTA/enanta-pharmac...

Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling Court invalidates Enanta's '953 patent claim against Pfizer's Paxlovid in major pharmaceutical patent dispute. Company plans to appeal federal court decision.

#ENTA Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

www.stocktitan.net/news/ENTA/enanta-pharmac...

JUST IN: ( NASDAQ: #ENTA ) Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

#StockMarket #News

#ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

www.stocktitan.net/news/ENTA/enanta-pharmac...